Vaxcyte Inc Insider Trading
Every director, officer and 10% holder of Vaxcyte Inc has to report each trade in its stock within two business days of making it. This is those filings.
PCVX on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Elvia CowanSVP, Finance & CAO2026-10-0519K shat $86.74 | Sale10b5-1 plan | $1.6M |
| Jim WassilEVP, Chief Scientific Ofc, COO2026-10-0518K shat $86.74 | Sale10b5-1 plan | $1.6M |
| Jim WassilEVP, Chief Scientific Ofc, COO2026-09-091.3K shat $59.52 | Sale | $79.4K |
| Jim WassilEVP, Chief Scientific Ofc, COO2026-09-041.4K shat $61.16 | Sale | $84.5K |
| Jim WassilCHIEF OPERATING OFFICER2026-09-011.5K shat $60.89 | Sale | $93.6K |
| Jim WassilCHIEF OPERATING OFFICER2026-09-01713 shat $61.48 | Sale | $43.8K |
| Jim WassilCHIEF OPERATING OFFICER2026-09-01924 shat $60.96 | Sale | $56.3K |
| Jim WassilCHIEF OPERATING OFFICER2026-09-01303 shat $61.42 | Sale | $18.6K |
| Harpreet S. DhaliwalChief Technical Ops Officer2026-08-0517K shat $55.00 | Sale10b5-1 plan | $935.1K |
| Jim WassilCHIEF OPERATING OFFICER2026-08-03861 shat $53.50 | Sale10b5-1 plan | $46.1K |
| Jim WassilCHIEF OPERATING OFFICER2026-08-031.4K shat $54.09 | Sale10b5-1 plan | $75.1K |
| Andrew GuggenhimePRESIDENT AND CFO2026-08-037K shat $53.76 | Sale10b5-1 plan | $374K |
| Andrew GuggenhimePRESIDENT AND CFO2026-08-033K shat $54.18 | Sale10b5-1 plan | $164.9K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-2711.8K shat $55.52 | Sale10b5-1 plan | $654.1K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-274.4K shat $55.93 | Sale10b5-1 plan | $246.9K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-27756 shat $55.52 | Sale10b5-1 plan | $42K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-27244 shat $55.96 | Sale10b5-1 plan | $13.7K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-27622 shat $55.54 | Sale10b5-1 plan | $34.5K |
| Grant PickeringCHIEF EXECUTIVE OFFICER2026-07-27378 shat $55.91 | Sale10b5-1 plan | $21.1K |
| Andrew GuggenhimePRESIDENT AND CFO2026-07-067.9K shat $57.16 | Sale10b5-1 plan | $452.3K |
| Andrew GuggenhimePRESIDENT AND CFO2026-07-062.1K shat $57.76 | Sale10b5-1 plan | $120.6K |
| Jim WassilCHIEF OPERATING OFFICER2026-07-011.8K shat $56.03 | Sale10b5-1 plan | $100.2K |
| Jim WassilCHIEF OPERATING OFFICER2026-07-01456 shat $57.47 | Sale10b5-1 plan | $26.2K |
| Jim WassilCHIEF OPERATING OFFICER2026-07-016 shat $57.82 | Sale10b5-1 plan | $346.9 |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on PCVX
Follow Vaxcyte Inc (PCVX) by email
New trades in Vaxcyte Inc (PCVX) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.